Mood, depression and suicidal thoughts on GLP-1 medicines: the FDA's 2026 label change

What the FDA did, and the evidence it cited

The warning sat on the three weight-loss GLP-1 labels: Saxenda, Wegovy and Zepbound. The FDA says labels for GLP-1 medicines approved for type 2 diabetes never carried it. The agency's Drug Safety Communication is dated January 13, 2026. The Wegovy (6/2026), Zepbound (8/2026) and Saxenda (6/2026) labels now list suicidal behavior and ideation as removed in February 2026, and none has a heading for it in Section 5.

These are the FDA's own descriptions. The Atlas read the FDA's summary, not the underlying analyses.

Europe reached a similar view earlier

The European Medicines Agency began a review in July 2023 after case reports involving liraglutide and semaglutide. In April 2024 its safety committee concluded that the evidence does not support a causal association between GLP-1 medicines and suicidal thoughts or self-injury, and that no update to the product information was warranted.

What the main studies found

The studies below ask the same question in different ways. The trial analyses can say more about cause but enrolled people without known major psychiatric illness. The record-based studies include more varied people but cannot rule out other explanations.

Adolescents

A 2026 meta-analysis of 11 studies in adolescents (9 randomized trials with 1,253 participants and 2 observational studies with 8,922) found no higher rate of suicide attempts or depressive symptoms with GLP-1 medicines, and a possibly lower rate of suicidal ideation (risk ratio 0.73, 95% CI 0.54 to 0.99). Its authors said the finding should be read cautiously.

What the labels say now

The FDA's change applies to three labels. Other weight-loss medicines have their own suicide-related text, which the FDA says remains in some labels.

Depression and mood, apart from suicidal thoughts

Suicidal thoughts are only part of the question. People also ask about depression, anxiety and feeling emotionally flat. The two post hoc analyses above measured depression with a standard questionnaire, and scores were slightly lower, not higher, on semaglutide and tirzepatide than on placebo, by less than one point on a 27-point scale. The semaglutide authors did not consider the difference clinically meaningful.

Two limits matter. Those trials enrolled people without known major psychiatric illness, so they say little about people with depression, bipolar disorder or past suicidal thoughts. And the observational studies, which draw on real-world records, disagree with one another in size and direction, which is why the reviews rate the certainty of the evidence low.

What the FDA tells patients

The FDA says people should continue taking their medicine as prescribed, discuss concerns with their health care professional, and tell their clinician about new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior. For clinicians, it says to refer anyone who discloses suicidal thoughts or behavior to a mental health professional. In the U.S., people in distress can call or text 988, the Suicide & Crisis Lifeline.

What people report

In online communities some people describe feeling flat, irritable or low after starting, while others describe mood lifting as weight, sleep and health improve. None of this was measured. Posts cannot separate the medicine from weight loss itself, life events or what a person was already living with. The side effects, week by week page covers what labels and trials list for the early weeks.

Quick answers

Do GLP-1 medicines cause suicidal thoughts?

The FDA's 2026 review of 91 trials and a database study of about 2.2 million new users found no increased risk, and the EMA reached a similar conclusion in 2024. Reviews of the research rate the certainty as low or very low and describe the result as no detected increase, not proof of no risk.

Why did the FDA remove the warning?

It said the pooled trials and the database study did not show an increased risk of suicidal thoughts, suicidal behavior or self-harm, and that the wider research does not support a causal link.

Does the FDA's change apply to all weight-loss medicines?

No. It covers Saxenda, Wegovy and Zepbound. Contrave, Qsymia and Imcivree still carry suicide-related text in their labels.

Do GLP-1 medicines cause depression?

In post hoc analyses of the STEP and SURMOUNT trials, depression scores were slightly lower on the medicines than on placebo. Observational studies vary, and reviews rate the certainty of the evidence low.

What about people with depression or past suicidal thoughts?

The trial analyses enrolled people without known major psychiatric illness, so they do not answer this well. A 2026 review calls for studies that include people with pre-existing psychiatric disorders. This is a conversation for a prescriber.

What did Europe decide?

In April 2024 the EMA's safety committee concluded that the evidence does not support a causal association between GLP-1 medicines and suicidal thoughts or self-injury, and that no update to product information was warranted.

What should I do if my mood changes?

The FDA says to tell a clinician about new or worsening depression, suicidal thoughts or unusual changes in mood or behavior. In the U.S., you can call or text 988 for immediate support.

Is the warning gone from the Wegovy pill label too?

Yes. One label covers the Wegovy injection and tablets, and it lists suicidal behavior and ideation as removed in February 2026.

Questions to ask

• I have a history of depression, anxiety or an eating disorder. Does that change the plan or how we check in?
• Which mood changes should I tell you about, and how soon?
• Who do I contact between visits if my mood drops?
• Do any of my other medicines affect mood, and do they need a second look as my weight changes?

What is still unknown

• The Atlas read the FDA's summary of its 91-trial analysis and database study, not the underlying analyses.
• How these medicines affect people with serious mental illness. The post hoc analyses enrolled people without known major psychiatric illness, and a 2026 review calls for studies that include them.
• Observational studies disagree in size and direction, and reviews rate the certainty of the evidence low or very low.
• Most trial data cover about one to two years of treatment.
• The FDA says similar language remains in some other weight-loss medicines' labels. The Atlas found no statement about changing them.
• Label text changes. The versions here were read in October 2026.